alexa RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer.
Biochemistry

Biochemistry

Clinical & Medical Biochemistry

Author(s): Sebova K, Zmetakova I, Bella V, Kajo K, Stankovicova I,

Abstract Share this page

Abstract Breast cancer is the most common cancer in women worldwide, representing 28.2\% of all female malignancies. In addition to genetic changes, epigenetic events, as aberrant DNA methylation and histone modification, are responsible for cancer development. Many tumour suppressor genes are inactivated by DNA hypermethylation, which could be utilized for identification of new epigenetic biomarkers. To investigate the relation between DNA methylation level and breast cancer progression, we analysed DNA methylation in RASSF1A and CDH1 promoters using quantitative multiplex methylation-specific PCR in paraffin-embedded tumour tissues and blood samples from 92 breast cancer patients and 50 controls, respectively. The associations between RASSF1A and CDH1 methylation levels and clinico-pathological parameters were tested by Kruskal-Wallis and van der Waerden ANOVA tests. Out of 92 breast cancer patients, 76 (82.6\%) manifested various levels of RASSF1A (range from 1.20 to 92.63\%) and 20 (21.7\%) of CDH1 (range from 1.20 to 79.62\%) methylation. However, no methylation was found in 50 controls. Increasing trends in RASSF1A methylation were observed in tumour size, lymph node status and TNM stage, but only CDH1 methylation levels showed statistically significant differences between the patient subgroups in lymph node status and IHC subtype. Overall, stable relatively high RASSF1A methylation could be utilised as universal tumour marker and the less frequent but highly methylated CDH1 promoter can serve for identification of potentially metastasising tumours. This article was published in Cancer Biomark and referenced in Clinical & Medical Biochemistry

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

  • 2nd International Conference on Biochemistry
    Sep 21-22, 2017 Macau, Hong Kong
  • 7th International Conference on Predictive, Preventive and Personalized Medicine & Molecular Diagnostics
    Oct 23-25, 2017 Chicago, USA
  • International Conference on Biotech Pharmaceuticals
    October 23-25, 2017 Paris, France

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords